<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Surg</journal-id><journal-id journal-id-type="iso-abbrev">Br J Surg</journal-id><journal-id journal-id-type="publisher-id">bjs</journal-id><journal-title-group><journal-title>The British Journal of Surgery</journal-title></journal-title-group><issn pub-type="ppub">0007-1323</issn><issn pub-type="epub">1365-2168</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39891429</article-id><article-id pub-id-type="pmc">PMC11785728</article-id><article-id pub-id-type="doi">10.1093/bjs/znae327</article-id><article-id pub-id-type="publisher-id">znae327</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00910</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>Bjs/3</subject></subj-group></article-categories><title-group><article-title>Preoperative stereotactic radiotherapy to prevent pancreatic fistula in high-risk patients undergoing pancreatoduodenectomy (FIBROPANC): prospective multicentre phase II single-arm trial</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7009-7034</contrib-id><name><surname>Wismans</surname><given-names>Leonoor V</given-names></name><aff>
<institution>Erasmus Medical Center Cancer Institute, Erasmus MC, University Medical Center Rotterdam</institution>, <addr-line>Rotterdam</addr-line>, <country country="NL">The Netherlands</country></aff><aff>
<institution>Department of Surgery, Erasmus MC, University Medical Center Rotterdam</institution>, <addr-line>Rotterdam</addr-line>, <country country="NL">The Netherlands</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0007-7418-3056</contrib-id><name><surname>Hendriks</surname><given-names>Tessa E</given-names></name><aff>
<institution>Department of Surgery, Amsterdam UMC, location University of Amsterdam</institution>, <addr-line>Amsterdam</addr-line>, <country country="NL">The Netherlands</country></aff><aff>
<institution>Cancer Center Amsterdam</institution>, <addr-line>Amsterdam</addr-line>, <country country="NL">The Netherlands</country></aff><aff>
<institution>Department of Surgery, Leiden University Medical Center</institution>, <addr-line>Leiden</addr-line>, <country country="NL">The Netherlands</country></aff><aff>
<institution>Dutch Institute for Clinical Auditing</institution>, <addr-line>Leiden</addr-line>, <country country="NL">The Netherlands</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2972-5622</contrib-id><name><surname>Suurmeijer</surname><given-names>J Annelie</given-names></name><aff>
<institution>Department of Surgery, Amsterdam UMC, location University of Amsterdam</institution>, <addr-line>Amsterdam</addr-line>, <country country="NL">The Netherlands</country></aff><aff>
<institution>Cancer Center Amsterdam</institution>, <addr-line>Amsterdam</addr-line>, <country country="NL">The Netherlands</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0002-5021-1597</contrib-id><name><surname>Nuyttens</surname><given-names>Joost J</given-names></name><aff>
<institution>Department of Radiation Oncology, Erasmus University Medical Center</institution>, <addr-line>Rotterdam</addr-line>, <country country="NL">The Netherlands</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7542-8920</contrib-id><name><surname>Bruynzeel</surname><given-names>Anna M</given-names></name><aff>
<institution>Department of Surgery, Amsterdam UMC, location University of Amsterdam</institution>, <addr-line>Amsterdam</addr-line>, <country country="NL">The Netherlands</country></aff><aff>
<institution>Department of Radiation Oncology, Amsterdam UMC, location Vrije Universiteit</institution>, <addr-line>Amsterdam</addr-line>, <country country="NL">The Netherlands</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5068-5517</contrib-id><name><surname>Intven</surname><given-names>Martijn P</given-names></name><aff>
<institution>Department of Radiation Oncology, University Medical Center Utrecht</institution>, <addr-line>Utrecht</addr-line>, <country country="NL">The Netherlands</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0616-7349</contrib-id><name><surname>van Driel</surname><given-names>Lydi M</given-names></name><aff>
<institution>Department of Gastroenterology and Hepatology, Erasmus University Medical Center</institution>, <addr-line>Rotterdam</addr-line>, <country country="NL">The Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Haen</surname><given-names>Roel</given-names></name><aff>
<institution>Erasmus Medical Center Cancer Institute, Erasmus MC, University Medical Center Rotterdam</institution>, <addr-line>Rotterdam</addr-line>, <country country="NL">The Netherlands</country></aff><aff>
<institution>Department of Surgery, Erasmus MC, University Medical Center Rotterdam</institution>, <addr-line>Rotterdam</addr-line>, <country country="NL">The Netherlands</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0003-0444-8697</contrib-id><name><surname>de Wilde</surname><given-names>Roeland F</given-names></name><aff>
<institution>Erasmus Medical Center Cancer Institute, Erasmus MC, University Medical Center Rotterdam</institution>, <addr-line>Rotterdam</addr-line>, <country country="NL">The Netherlands</country></aff><aff>
<institution>Department of Surgery, Erasmus MC, University Medical Center Rotterdam</institution>, <addr-line>Rotterdam</addr-line>, <country country="NL">The Netherlands</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1917-6973</contrib-id><name><surname>Groot Koerkamp</surname><given-names>Bas</given-names></name><aff>
<institution>Erasmus Medical Center Cancer Institute, Erasmus MC, University Medical Center Rotterdam</institution>, <addr-line>Rotterdam</addr-line>, <country country="NL">The Netherlands</country></aff><aff>
<institution>Department of Surgery, Erasmus MC, University Medical Center Rotterdam</institution>, <addr-line>Rotterdam</addr-line>, <country country="NL">The Netherlands</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9605-6831</contrib-id><name><surname>Busch</surname><given-names>Olivier R</given-names></name><aff>
<institution>Department of Surgery, Amsterdam UMC, location University of Amsterdam</institution>, <addr-line>Amsterdam</addr-line>, <country country="NL">The Netherlands</country></aff><aff>
<institution>Cancer Center Amsterdam</institution>, <addr-line>Amsterdam</addr-line>, <country country="NL">The Netherlands</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9822-3784</contrib-id><name><surname>Stoker</surname><given-names>Jaap</given-names></name><aff>
<institution>Cancer Center Amsterdam</institution>, <addr-line>Amsterdam</addr-line>, <country country="NL">The Netherlands</country></aff><aff>
<institution>Department of Radiology and Nuclear Medicine, Amsterdam UMC, location University of Amsterdam</institution>, <addr-line>Amsterdam</addr-line>, <country country="NL">The Netherlands</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1283-630X</contrib-id><name><surname>Verheij</surname><given-names>Joanne</given-names></name><aff>
<institution>Cancer Center Amsterdam</institution>, <addr-line>Amsterdam</addr-line>, <country country="NL">The Netherlands</country></aff><aff>
<institution>Department of Pathology, Amsterdam UMC, location University of Amsterdam</institution>, <addr-line>Amsterdam</addr-line>, <country country="NL">The Netherlands</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4307-1568</contrib-id><name><surname>Farina</surname><given-names>Arantza</given-names></name><aff>
<institution>Cancer Center Amsterdam</institution>, <addr-line>Amsterdam</addr-line>, <country country="NL">The Netherlands</country></aff><aff>
<institution>Department of Pathology, Amsterdam UMC, location University of Amsterdam</institution>, <addr-line>Amsterdam</addr-line>, <country country="NL">The Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>de Boer</surname><given-names>Onno J</given-names></name><aff>
<institution>Cancer Center Amsterdam</institution>, <addr-line>Amsterdam</addr-line>, <country country="NL">The Netherlands</country></aff><aff>
<institution>Department of Pathology, Amsterdam UMC, location University of Amsterdam</institution>, <addr-line>Amsterdam</addr-line>, <country country="NL">The Netherlands</country></aff></contrib><contrib contrib-type="author"><name><surname>Doukas</surname><given-names>Michail</given-names></name><aff>
<institution>Erasmus Medical Center Cancer Institute, Erasmus MC, University Medical Center Rotterdam</institution>, <addr-line>Rotterdam</addr-line>, <country country="NL">The Netherlands</country></aff><aff>
<institution>Department of Pathology, Erasmus University Medical Center</institution>, <addr-line>Rotterdam</addr-line>, <country country="NL">The Netherlands</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2112-4390</contrib-id><name><surname>de Hingh</surname><given-names>Ignace H</given-names></name><aff>
<institution>Department of Surgery, Catharina Hospital, Catharina Cancer Institute</institution>, <addr-line>Eindhoven</addr-line>, <country country="NL">The Netherlands</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7515-9276</contrib-id><name><surname>Lips</surname><given-names>Daan J</given-names></name><aff>
<institution>Department of Surgery, Medisch Spectrum Twente</institution>, <addr-line>Enschede</addr-line>, <country country="NL">The Netherlands</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1317-5614</contrib-id><name><surname>van der Harst</surname><given-names>Erwin</given-names></name><aff>
<institution>Department of Surgery, Maasstad Hospital</institution>, <addr-line>Rotterdam</addr-line>, <country country="NL">The Netherlands</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2516-2263</contrib-id><name><surname>van Tienhoven</surname><given-names>Geertjan</given-names></name><aff>
<institution>Department of Surgery, Amsterdam UMC, location University of Amsterdam</institution>, <addr-line>Amsterdam</addr-line>, <country country="NL">The Netherlands</country></aff><aff>
<institution>Department of Radiation Oncology, Amsterdam UMC, location University of Amsterdam</institution>, <addr-line>Amsterdam</addr-line>, <country country="NL">The Netherlands</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9511-2157</contrib-id><name><surname>van Eijck</surname><given-names>Casper H</given-names></name><aff>
<institution>Erasmus Medical Center Cancer Institute, Erasmus MC, University Medical Center Rotterdam</institution>, <addr-line>Rotterdam</addr-line>, <country country="NL">The Netherlands</country></aff><aff>
<institution>Department of Surgery, Erasmus MC, University Medical Center Rotterdam</institution>, <addr-line>Rotterdam</addr-line>, <country country="NL">The Netherlands</country></aff></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2650-9350</contrib-id><name><surname>Besselink</surname><given-names>Marc G</given-names></name><aff>
<institution>Department of Surgery, Amsterdam UMC, location University of Amsterdam</institution>, <addr-line>Amsterdam</addr-line>, <country country="NL">The Netherlands</country></aff><aff>
<institution>Cancer Center Amsterdam</institution>, <addr-line>Amsterdam</addr-line>, <country country="NL">The Netherlands</country></aff><xref rid="znae327-AFN1" ref-type="author-notes"/><xref rid="znae327-cor1" ref-type="corresp"/><!--m.g.besselink@amsterdamUMC.nl--><on-behalf-of>on behalf of</on-behalf-of></contrib><contrib contrib-type="author"><collab>the Dutch Pancreatic Cancer Group
<contrib-group><contrib contrib-type="author"><name><surname>Comandatore</surname><given-names>Annalisa</given-names></name></contrib></contrib-group></collab></contrib></contrib-group><author-notes><corresp id="znae327-cor1">
<italic toggle="yes">Correspondence to:</italic> Marc G. Besselink, Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, De Boelelaan 1117 (ZH-7F), Amsterdam, 1081 HV, The Netherlands (e-mail: <email>m.g.besselink@amsterdamumc.nl</email>)</corresp><fn id="znae327-AFN1"><p>Members of the [on behalf of the Dutch Pancreatic Cancer Group] are co-authors of this study and are listed under the heading Collaborators.</p></fn></author-notes><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><pub-date pub-type="epub" iso-8601-date="2025-02-01"><day>01</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>01</day><month>2</month><year>2025</year></pub-date><volume>112</volume><issue>2</issue><elocation-id>znae327</elocation-id><history><date date-type="received"><day>13</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>18</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>18</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025. Published by Oxford University Press on behalf of BJS Foundation Ltd.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="znae327.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>Postoperative pancreatic fistula is the main driver of morbidity and mortality after pancreatoduodenectomy. In high-risk patients, the rate of postoperative pancreatic fistula approaches 50%, whereas it is below 5% in patients with pancreatic cancer who receive neoadjuvant chemoradiotherapy. The aim of this study was to evaluate the safety, feasibility, and efficacy of preoperative stereotactic body radiotherapy on the pancreatic neck transection margin in high-risk patients undergoing pancreatoduodenectomy to prevent postoperative pancreatic fistula.</p></sec><sec id="s2"><title>Methods</title><p>In this prospective multicentre open-label single-arm trial (progressing from a safety run-in phase to a phase II design), patients undergoing pancreatoduodenectomy for neoplasms other than pancreatic ductal adenocarcinoma received a single preoperative stereotactic body radiotherapy dose of 12&#x02005;Gy. Primary endpoints included safety (less than or equal to 15% grade 3&#x02013;5 toxicity), feasibility (a significant change in pancreatic texture measured using a durometer), and efficacy (a 15% reduction in the grade B/C postoperative pancreatic fistula rate compared with patients from the Dutch Pancreatic Cancer Audit who were eligible but not included in this study). Secondary endpoints assessed tissue fibrosis (collagen density).</p></sec><sec id="s3"><title>Results</title><p>Overall, 38 patients were included, of whom 33 (87%) completed the study protocol and were included in the per-protocol analysis. The safety cut-off was met, with 3% grade 3&#x02013;5 toxicity. Pancreatic tissue treated with stereotactic body radiotherapy showed increased firmness using a durometer (median of 47 (interquartile range 36&#x02013;57) <italic toggle="yes">versus</italic> 37 (interquartile range 30&#x02013;41) Shore OO units; <italic toggle="yes">P</italic> &#x0003c; 0.001) and a higher collagen density (median of 6.1% (interquartile range 4.4%&#x02013;9.5%) <italic toggle="yes">versus</italic> 4.6% (interquartile range 2.5%&#x02013;7.4%); <italic toggle="yes">P</italic> = 0.003). The grade B/C postoperative pancreatic fistula rate with stereotactic body radiotherapy was 57.6% (95% c.i. 41% to 74%), compared with 34% (95% c.i. 27% to 42%) in audit controls (<italic toggle="yes">P</italic> = 0.011).</p></sec><sec id="s4"><title>Conclusion</title><p>Preoperative stereotactic body radiotherapy is safe in high-risk patients undergoing pancreatoduodenectomy and increases parenchymal firmness and fibrosis, but fails to show evidence of efficacy.</p></sec></abstract><abstract abstract-type="teaser"><p>The FIBROPANC study investigated the safety, feasibility, and efficacy of preoperative stereotactic radiotherapy on the pancreatic neck transection margin to reduce postoperative pancreatic fistula in high-risk patients undergoing pancreatoduodenectomy. A single fraction of high-dose stereotactic body radiotherapy increased parenchymal firmness and fibrosis, but did not reduce the postoperative pancreatic fistula rate.</p></abstract><counts><page-count count="9"/></counts></article-meta></front><body><sec sec-type="intro" id="znae327-s1"><title>Introduction</title><p>Postoperative pancreatic fistula (POPF) remains the primary driver of morbidity and mortality after pancreatoduodenectomy<sup><xref rid="znae327-B1" ref-type="bibr">1&#x02013;3</xref></sup>. The healthcare costs of one episode of POPF amount to 20,000&#x02013;50,000 US dollars<sup><xref rid="znae327-B4" ref-type="bibr">4</xref>,<xref rid="znae327-B5" ref-type="bibr">5</xref></sup>. Despite numerous trials attempting to optimize surgical techniques, timely percutaneous drainage, and pharmacological interventions, the risk and severity of POPF after pancreatoduodenectomy did not decline<sup><xref rid="znae327-B6" ref-type="bibr">6</xref>,<xref rid="znae327-B7" ref-type="bibr">7</xref></sup>. Therefore, there is an urgent need for effective perioperative interventions to reduce the risk of POPF, especially in high-risk patients.</p><p>In recent studies, preoperative chemoradiotherapy was associated with a reduced rate of POPF in patients with pancreatic cancer<sup><xref rid="znae327-B8" ref-type="bibr">8&#x02013;10</xref></sup>. The suggested protective effect of radiotherapy is likely mediated through the induction of fibrosis<sup><xref rid="znae327-B11" ref-type="bibr">11</xref>,<xref rid="znae327-B12" ref-type="bibr">12</xref></sup>. Radiation-induced fibrosis could increase parenchymal firmness and prevent tearing by increasing the suture hold capacity. However, there are no oncological indications for preoperative chemoradiotherapy in patients undergoing pancreatoduodenectomy for indications other than pancreatic cancer.</p><p>Patients with diagnoses other than pancreatic cancer requiring pancreatoduodenectomy have a much higher risk of developing POPF<sup><xref rid="znae327-B13" ref-type="bibr">13</xref>,<xref rid="znae327-B14" ref-type="bibr">14</xref></sup>. Prominent risk factors for POPF include a soft pancreatic parenchyma and a small main pancreatic duct (MPD) diameter of less than or equal to 3&#x02005;mm, classified as &#x02018;grade D&#x02019; by the International Study Group for Pancreatic Surgery (ISGPS)<sup><xref rid="znae327-B15" ref-type="bibr">15</xref>,<xref rid="znae327-B16" ref-type="bibr">16</xref></sup>. The POPF risk in this patient category increases to over 30%<sup><xref rid="znae327-B16" ref-type="bibr">16</xref></sup>. Yet, prospective studies using preoperative radiotherapy to reduce the rate of POPF in these high-risk patients are lacking.</p><p>Stereotactic body radiotherapy (SBRT) offers precise targeting and concentrated high doses of radiation. The authors hypothesize that a single fraction of SBRT targeted at a 4&#x02005;cm area centred around the future transection site of the pancreas (that is the neck) may cause local fibrosis, resulting in firmer pancreatic tissue, which might reduce the risk of POPF. To evaluate radiotherapy-induced changes in pancreatic tissue and their impact on the development of POPF, standardized methods to quantify firmness and fibrosis are needed. However, the assessment of pancreatic firmness relies solely on a surgeon&#x02019;s subjective evaluation, as methods to assess pancreatic texture are lacking<sup><xref rid="znae327-B17" ref-type="bibr">17&#x02013;19</xref></sup>.</p><p>The aim of this study was to investigate the safety, feasibility, and efficacy of single-fraction SBRT targeted at the future pancreatic transection site to reduce the risk of POPF in patients at high risk undergoing pancreatoduodenectomy for (pre-)malignant tumours other than pancreatic cancer, including objective measurement of pancreatic texture and fibrosis.</p></sec><sec sec-type="methods" id="znae327-s2"><title>Methods</title><p>FIBROPANC was a prospective multicentre open-label single-arm trial (progressing from a safety run-in phase to a phase II design). Patients scheduled for pancreatoduodenectomy at high risk of developing POPF received preoperative, single-fraction SBRT at the future pancreatic neck transection site. The study protocol has been published previously<sup><xref rid="znae327-B20" ref-type="bibr">20</xref></sup>. The initial phase aimed to assess safety and feasibility; if safety and feasibility criteria were met, additional patients were enrolled to evaluate the intervention&#x02019;s efficacy in reducing grade B/C POPF.</p><sec id="znae327-s2.1"><title>Study population</title><p>Eligible patients included those scheduled for pancreatoduodenectomy for a (pre-)malignant tumour other than pancreatic ductal adenocarcinoma, with an MPD diameter of less than or equal to 3&#x02005;mm. Additional inclusion criteria were a WHO performance status of less than or equal to grade 2, age greater than or equal to 18 years, and suitability to undergo both SBRT and pancreatoduodenectomy. Exclusion criteria included patients undergoing pancreatoduodenectomy for (suspected) pancreatic ductal adenocarcinoma, chronic pancreatitis, or benign neoplasms. The study ran between March 2021 and July 2023.</p></sec><sec id="znae327-s2.2"><title>Study intervention and protocol completion</title><p>The SBRT was delivered in a single fraction of 12&#x02005;Gy. The dosage was calculated as described previously<sup><xref rid="znae327-B20" ref-type="bibr">20</xref></sup> and was delivered using MRI-guided SBRT or CyberKnife. CyberKnife was performed using fiducial markers in the pancreas (endoscopic ultrasound (EUS)-guided placement), plastic fiducial clips in the duodenum (endoscopic placement), or CT-guided internal target volume (non-invasive). MRI-guided SBRT was a non-invasive procedure. The gross target volume (GTV) included the middle of the pancreatic corpus, covering the intended location of the pancreatic-enteric anastomosis&#x02014;4&#x02005;cm towards the spleen from the right-sided border of the portal vein (<italic toggle="yes"><xref rid="znae327-F1" ref-type="fig">Fig. 1</xref></italic>). The study protocol describes additional target volumes, treatment planning, and dose prescription information<sup><xref rid="znae327-B20" ref-type="bibr">20</xref></sup>. Surgery was scheduled at least 4 weeks after SBRT to allow fibrosis to develop; if possible, an interval of 6 weeks was maintained in the case of premalignant disease. Protocol completion was defined as the ability to receive SBRT and maintain a post-SBRT interval of 4 weeks without causing any additional delay of the scheduled pancreatoduodenectomy.</p><fig position="float" id="znae327-F1" fig-type="figure"><label>Fig. 1</label><caption><p>Gross target volume for stereotactic body radiotherapy: from the right-sided border of the portal vein 4&#x02005;cm towards the spleen</p></caption><graphic xlink:href="znae327f1" position="float"/></fig></sec><sec id="znae327-s2.3"><title>Primary outcomes</title><sec id="znae327-s2.3.1"><title>Safety</title><p>For safety, all toxicities of grade 3&#x02013;5 potentially related to the preparation or administration of SBRT in all included patients (intention-to-treat analysis) were considered events. All toxicities occurring up to surgery or at least 21 days after SBRT administration were collected. The potential relation to SBRT of all intraoperative and postoperative complications occurring within 30 days after surgery was evaluated to ensure that indirect toxicities of the study treatment were also documented. Safety was reached if less than or equal to 15% of patients experienced grade 3&#x02013;5 study intervention-related toxicity.</p></sec><sec id="znae327-s2.3.2"><title>Feasibility</title><p>The intervention&#x02019;s proof of principle was represented by the feasibility, defined as a significant change in pancreatic texture between the resection site (the irradiated tissue) and the uncinate process (the non-irradiated tissue) within the same patient using a durometer (Model DD-4 Digital Durometer Type Shore OO, Rex Gauge Company, Lake Zurich, 11, USA).</p></sec><sec id="znae327-s2.3.3"><title>Efficacy</title><p>Efficacy was defined as a grade B/C POPF risk reduction of 15% from the population risk in audit controls. Data from the Dutch Pancreatic Cancer Audit (DPCA) was used to calculate a population risk for patients that met the study inclusion criteria during the study interval (that is MPD less than or equal to 3&#x02005;mm and a diagnosis other than pancreatic ductal adenocarcinoma operated on within the participating study centres, during the study interval). Before the study interval (2014&#x02013;2018), the predefined population risk was considered greater than 25%, as described in the study protocol<sup><xref rid="znae327-B20" ref-type="bibr">20</xref></sup>.</p></sec></sec><sec id="znae327-s2.4"><title>Secondary outcomes</title><sec id="znae327-s2.4.1"><title>Assessment of firmness, fibrosis, and pancreatitis</title><p>Several techniques were implemented to evaluate the SBRT-induced effect on pancreatic tissue. First, intraoperatively, the surgeon assessed whether palpable local fibrosis was present and assessed any visual impact of SBRT at the pancreatic neck transection site (the irradiated field) compared with the uncinate process (the non-irradiated field). Secondly, a sample from the resection site (an irradiated sample) and a sample from the uncinate process (a non-irradiated sample) were taken during the processing of the specimen, as described in the study protocol<sup><xref rid="znae327-B20" ref-type="bibr">20</xref></sup>. The pathologist examined both samples for fibrosis macroscopically.</p><p>Third, the durometer was used to quantify the effect of radiotherapy on pancreatic texture. The correlation between durometric measurement and surgeon evaluation was demonstrated in previous studies<sup><xref rid="znae327-B18" ref-type="bibr">18</xref>,<xref rid="znae327-B19" ref-type="bibr">19</xref>,<xref rid="znae327-B21" ref-type="bibr">21</xref></sup>. Durometric measurement was standardized using an operating stand to optimize validity and minimize inter-observer bias (<xref rid="sup1" ref-type="supplementary-material">Figure S1</xref>). Durometer values were measured in Shore OO units, ranging from 0 (soft) to 100 (firm). The mean result of three repeated measurements per sample at the resection site (the irradiated tissue) and the uncinate process (the non-irradiated tissue) within the same patient was documented. The standard operating procedure for sample collection and durometric measurement can be found in the study protocol<sup><xref rid="znae327-B20" ref-type="bibr">20</xref></sup>. Fourth, histopathological evaluation using Picrosirius red staining was conducted objectively to quantify collagen, the main component of fibrosis. Slides from both samples were stained to identify post-radiation differences in collagen content. Histology slides were digitised using a Philips Ultrafast Scanner (Philips Digital Pathology Systems, Best, the Netherlands) at 40x resolution (0.25 microns/pixel). All slide images were converted to BigTiff, and the total tissue area and the amount of Picrosirius red staining were quantified using QuPath v0.5.1 and expressed as a percentage of positive staining.<sup><xref rid="znae327-B22" ref-type="bibr">22</xref></sup></p><p>Fifth, Haematoxylin and eosin (H &#x00026; E)-stained slides were assessed, focusing on histopathological features indicative of pancreatitis in the irradiated sample compared with the non-irradiated sample. Additionally, durometric measurement and picrosirius red staining were performed for control patients. Control samples were collected from eligible patients who did not receive the study intervention.</p></sec><sec id="znae327-s2.4.2"><title>Additional outcomes</title><p>Other outcomes included major complications, pancreatic surgery-related complications up to 30 days after surgery or during hospital stay, duration of hospital stay, and readmission rate within 30 days after discharge. Pancreatic surgery-related complications included POPF<sup><xref rid="znae327-B2" ref-type="bibr">2</xref></sup>, post-pancreatectomy haemorrhage (PPH)<sup><xref rid="znae327-B23" ref-type="bibr">23</xref></sup>, chyle leakage<sup><xref rid="znae327-B24" ref-type="bibr">24</xref></sup>, bile leakage<sup><xref rid="znae327-B25" ref-type="bibr">25</xref></sup>, and delayed gastric emptying (DGE)<sup><xref rid="znae327-B26" ref-type="bibr">26</xref></sup>, all defined as grade B/C according to the ISGPS or International Study Group of Liver Surgery (ISGLS) criteria. Mortality included in-hospital/30-day mortality rates (that is in-hospital mortality during primary admission) and 90-day mortality rates. Postoperative measurements of HbA1c for new-onset diabetes mellitus and faecal elastase levels for exocrine pancreatic function were in accordance with institutional standards.</p></sec></sec><sec id="znae327-s2.5"><title>Ethical approval, data, and sample collection</title><p>This study was performed in line with the principles of the Declaration of Helsinki<sup><xref rid="znae327-B27" ref-type="bibr">27</xref></sup>. The Dutch Pancreatic Cancer Group (DPCG) supported the study. The institutional review boards of both participating centres approved the study protocol and amendments (Amsterdam UMC MEC 2020-079 and Erasmus MC MEC 2020-0688). The trial was registered on the Central Committee on Research Involving Human Subjects Register with trial number NL72913 and on <ext-link xlink:href="https://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> with trial number NCT05641233. Biomaterials of control patients were included in the biobank (Amsterdam UMC MEC 2014-094 and Erasmus MC MEC 2015-085). All patients provided written informed consent. Study baseline characteristics included sex, age during surgery, BMI, WHO performance status, ASA grade, Charlson co-morbidity index, and postoperative histopathological diagnosis. Treatment characteristics included SBRT type, marker placement, interval between SBRT and surgery, surgical approach, and MPD diameter at the pancreatic neck. Perioperative characteristics included use of somatostatin analogues, intraoperative drain placement, and pancreatic texture.</p></sec><sec id="znae327-s2.6"><title>Sample size calculation</title><p>Of the 20 patients eligible for the safety run-in phase, it was considered acceptable for up to 3 patients (less than or equal to 15%) to experience grade 3&#x02013;5 toxicity related to the intervention, based on an expected 15% reduction in POPF. For feasibility, a one-sample <italic toggle="yes">t</italic> test with a 5% one-sided significance level had 80% power to detect the difference between a null hypothesis mean of 11 and an alternative mean of 25 (using a durometer), assuming that the standard deviation was 21 based on previous literature<sup><xref rid="znae327-B19" ref-type="bibr">19</xref>,<xref rid="znae327-B20" ref-type="bibr">20</xref></sup>. For the second phase, focusing on clinical efficacy, an additional 13 patients were needed to calculate a reduction of 15% in POPF in 33 patients (&#x003b1; 0.05, power 0.80), with an intended 15% reduction. Flemming&#x02019;s procedure was used for calculation. Complete safety, feasibility, and POPF measurements were required in 33 patients who completed the study protocol to prevent type II errors. Patients were replaced if an endpoint could not be evaluated (for example patients did not undergo resection due to the discovery of metastases during exploratory laparotomy or withdrawal of informed consent before the intervention) or if they underwent surgery within 4 weeks after SBRT.</p></sec><sec id="znae327-s2.7"><title>Statistical analysis</title><p>Continuous data are presented as median (interquartile range (i.q.r.)) and categorical data are presented as <italic toggle="yes">n</italic> (%). Differences in durometer outcomes and picrosirius red density were determined using Wilcoxon matched-pairs signed rank tests. For statistical analysis, <italic toggle="yes">P</italic> &#x0003c; 0.050 was deemed significant. All statistical tests were two-tailed and analysis was performed using R statistical software (version 4.1.1). Figures were made using GraphPad Prism software (version 8.0).</p></sec></sec><sec sec-type="results" id="znae327-s3"><title>Results</title><p>This phase II study included 38 patients from two centres after the safety run-in phase demonstrated the intervention&#x02019;s safety and feasibility. Of the 38 patients who were included, 33 (86.8%) completed the study protocol and were included in the per-protocol analysis. In four patients (10.5%), the time between SBRT and surgery was less than 4 weeks and one patient (2.6%) did not receive SBRT due to post-EUS-guided fiducial marker placement-induced pancreatitis. The study flow chart is shown in <italic toggle="yes"><xref rid="znae327-F2" ref-type="fig">Fig. 2</xref></italic>. The median age of the patients was 69 (i.q.r. 61&#x02013;72) years and 24 patients (63.2%) were men. Most patients (63%) had an ASA grade between 0&#x02013;II and the most common postoperative histopathological diagnoses were cholangiocarcinoma (9 patients, 23.7%) and duodenal adenocarcinoma (9 patients, 23.7%) (<italic toggle="yes"><xref rid="znae327-T1" ref-type="table">Table 1</xref></italic>).</p><fig position="float" id="znae327-F2" fig-type="figure"><label>Fig. 2</label><caption><p>Study flow chart</p><p>SBRT, stereotactic body radiotherapy.</p></caption><graphic xlink:href="znae327f2" position="float"/></fig><table-wrap position="float" id="znae327-T1"><label>Table 1</label><caption><p>Baseline characteristics</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">All patients (<italic toggle="yes">n</italic> = 38)</th><th align="center" rowspan="1" colspan="1">Per-protocol (<italic toggle="yes">n</italic> = 33)</th></tr></thead><tbody><tr><td colspan="3" rowspan="1">
<bold>Sex</bold>
</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Male</td><td rowspan="1" colspan="1">24 (63.2)</td><td rowspan="1" colspan="1">21 (63.6)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Female</td><td rowspan="1" colspan="1">14 (36.8)</td><td rowspan="1" colspan="1">12 (36.4)</td></tr><tr><td rowspan="1" colspan="1">Age (years), median (i.q.r.)</td><td rowspan="1" colspan="1">69 (61&#x02013;72)</td><td rowspan="1" colspan="1">69 (66&#x02013;72)</td></tr><tr><td rowspan="1" colspan="1">BMI &#x0003e;25&#x02005;kg/m<sup>2</sup></td><td rowspan="1" colspan="1">15 (39.5)</td><td rowspan="1" colspan="1">11 (33.3)</td></tr><tr><td colspan="3" rowspan="1">
<bold>WHO performance status</bold>
</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Fully independent</td><td rowspan="1" colspan="1">8 (21.1)</td><td rowspan="1" colspan="1">8 (24.2)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Partially independent</td><td rowspan="1" colspan="1">30 (78.9)</td><td rowspan="1" colspan="1">30 (75.8)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Fully dependent</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td colspan="3" rowspan="1">
<bold>ASA grade</bold>
</td></tr><tr><td rowspan="1" colspan="1">&#x02003;0&#x02013;II</td><td rowspan="1" colspan="1">24 (63)</td><td rowspan="1" colspan="1">28 (84.8)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;III&#x02013;IV</td><td rowspan="1" colspan="1">14 (37)</td><td rowspan="1" colspan="1">13 (39.4)</td></tr><tr><td colspan="3" rowspan="1">
<bold>Charlson co-morbidity index</bold>
</td></tr><tr><td rowspan="1" colspan="1">&#x02003;0&#x02013;1</td><td rowspan="1" colspan="1">33 (86.8)</td><td rowspan="1" colspan="1">28 (84.8)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02265;2</td><td rowspan="1" colspan="1">5 (13.2)</td><td rowspan="1" colspan="1">5 (15.2)</td></tr><tr><td colspan="3" rowspan="1">
<bold>Postoperative pathology</bold>
</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Cholangiocarcinoma</td><td rowspan="1" colspan="1">9 (23.7)</td><td rowspan="1" colspan="1">8 (24.2)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Duodenal adenocarcinoma</td><td rowspan="1" colspan="1">9 (23.7)</td><td rowspan="1" colspan="1">7 (21.2)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Papillary cancer</td><td rowspan="1" colspan="1">7 (18.4)</td><td rowspan="1" colspan="1">5 (15.2)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Neuroendocrine neoplasm</td><td rowspan="1" colspan="1">5 (13.2)</td><td rowspan="1" colspan="1">5 (15.2)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;IPMN, SPN, or MCN</td><td rowspan="1" colspan="1">2 (5.3)</td><td rowspan="1" colspan="1">2 (6.1)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Pancreatic adenocarcinoma</td><td rowspan="1" colspan="1">1 (2.6)</td><td rowspan="1" colspan="1">1 (3.0)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Other*</td><td rowspan="1" colspan="1">5 (13.2)</td><td rowspan="1" colspan="1">5 (13.2)</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><p>Values are <italic toggle="yes">n</italic> (%) unless otherwise indicated. *Papillary adenoma, low-grade dysplasia, and no disease. i.q.r., interquartile range; IPMN, intraductal papillary mucinous neoplasm; SPN, solid pseudopapillary neoplasm, MCN, mucinous cystic neoplasm.</p></fn></table-wrap-foot></table-wrap><sec id="znae327-s3.1"><title>Study intervention</title><p>Of the 38 patients who were included, 37 (97.3%) received a single dose of 12&#x02005;Gy SBRT before surgery using MRI-guided SBRT (16 patients, 42.1%) or CyberKnife (21 patients, 55.3%). CyberKnife was performed using fiducial markers in six patients (16%)&#x02014;EUS-guided in the pancreas (5 patients) or endoscopically in the duodenum (1 patient). Most patients (32 patients, 84%) were treated using MRI-guided SBRT or CyberKnife without fiducial markers. The median time from the date of surgical indication to SBRT was 15 (i.q.r. 7&#x02013;22) days. In the per-protocol population, the median interval between SBRT and surgery was 5.8 (i.q.r. 4.6&#x02013;6.4) weeks (<italic toggle="yes"><xref rid="znae327-T2" ref-type="table">Table 2</xref></italic> and <italic toggle="yes"><xref rid="znae327-T3" ref-type="table">Table 3</xref></italic>).</p><table-wrap position="float" id="znae327-T2"><label>Table 2</label><caption><p>Treatment and perioperative characteristics</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">All patients (<italic toggle="yes">n</italic> = 38)</th><th align="center" rowspan="1" colspan="1">Per-protocol (<italic toggle="yes">n</italic> = 33)</th></tr></thead><tbody><tr><td colspan="3" rowspan="1">
<bold>Type of SBRT</bold>
</td></tr><tr><td rowspan="1" colspan="1">&#x02003;MRI-guided</td><td rowspan="1" colspan="1">16 (42.1)</td><td rowspan="1" colspan="1">15 (45.5)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;CyberKnife</td><td rowspan="1" colspan="1">21 (55.3)</td><td rowspan="1" colspan="1">18 (54.5)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;No SBRT</td><td rowspan="1" colspan="1">1 (2.6)</td><td rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td colspan="3" rowspan="1">
<bold>Fiducial marker placement</bold>
</td></tr><tr><td rowspan="1" colspan="1">&#x02003;EUS-guided</td><td rowspan="1" colspan="1">5 (13.2)</td><td rowspan="1" colspan="1">4 (12.1)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Endoscopic fiducial clip placement</td><td rowspan="1" colspan="1">1 (2.6)</td><td rowspan="1" colspan="1">1 (3.0)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;No fiducial marker placement</td><td rowspan="1" colspan="1">32 (84.2)</td><td rowspan="1" colspan="1">28 (84.8)</td></tr><tr><td rowspan="1" colspan="1">Interval between inclusion and SBRT (days), median (i.q.r.)</td><td rowspan="1" colspan="1">15 (7&#x02013;22)</td><td rowspan="1" colspan="1">15 (7&#x02013;22)</td></tr><tr><td rowspan="1" colspan="1">Interval between SBRT and surgery (weeks), median (i.q.r.)</td><td rowspan="1" colspan="1">5.4 (4.4&#x02013;6.4)</td><td rowspan="1" colspan="1">5.8 (4.6&#x02013;6.4)</td></tr><tr><td colspan="3" rowspan="1">
<bold>Surgical approach to pancreatoduodenectomy</bold>
</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Open</td><td rowspan="1" colspan="1">14 (36.8)</td><td rowspan="1" colspan="1">12 (36.4)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Robot-assisted</td><td rowspan="1" colspan="1">22 (57.9)</td><td rowspan="1" colspan="1">21 (63.6)</td></tr><tr><td rowspan="1" colspan="1">Diameter of the main pancreatic duct at the pancreatic neck (mm), median (i.q.r.)</td><td rowspan="1" colspan="1">3.0 (2.0&#x02013;3.0)</td><td rowspan="1" colspan="1">3.0 (2.0&#x02013;3.0)</td></tr><tr><td rowspan="1" colspan="1">Use of somatostatin analogues</td><td rowspan="1" colspan="1">21 (62)</td><td rowspan="1" colspan="1">20 (60.6)</td></tr><tr><td rowspan="1" colspan="1">Intraoperative drain placement</td><td rowspan="1" colspan="1">21 (55.2)</td><td rowspan="1" colspan="1">20 (60.6)</td></tr><tr><td rowspan="1" colspan="1">Intraoperative blood loss (ml), median (i.q.r.)</td><td rowspan="1" colspan="1">400 (210&#x02013;700)</td><td rowspan="1" colspan="1">300 (175&#x02013;600)</td></tr><tr><td rowspan="1" colspan="1">Intraoperative time (min), median (i.q.r.)</td><td rowspan="1" colspan="1">352 (245&#x02013;467)</td><td rowspan="1" colspan="1">354 (278&#x02013;444)</td></tr><tr><td colspan="3" rowspan="1">
<bold>Pancreatic texture</bold>
</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Soft/normal</td><td rowspan="1" colspan="1">34 (89.5)</td><td rowspan="1" colspan="1">30 (90.9)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Firm</td><td rowspan="1" colspan="1">4 (10.5)</td><td rowspan="1" colspan="1">3 (9.1)</td></tr><tr><td colspan="3" rowspan="1">
<bold>Surgeon assessment, local firmness*</bold>
</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;No</td><td rowspan="1" colspan="1">32 (84.8)</td><td rowspan="1" colspan="1">28 (84.8)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;Yes, more firm</td><td rowspan="1" colspan="1">6 (15.6)</td><td rowspan="1" colspan="1">5 (15.1)</td></tr><tr><td colspan="3" rowspan="1">
<bold>Surgeon assessment, local visual effects*</bold>
</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;No effects</td><td rowspan="1" colspan="1">32 (84.2)</td><td rowspan="1" colspan="1">27 (81.8)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;Oedema</td><td rowspan="1" colspan="1">1 (2.6)</td><td rowspan="1" colspan="1">1 (3.0)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;Thickening of the main pancreatic duct</td><td rowspan="1" colspan="1">5 (13.2)</td><td rowspan="1" colspan="1">4 (12.1)</td></tr><tr><td colspan="3" rowspan="1">
<bold>Pathological assessment, macroscopic fibrosis&#x02020;</bold>
</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;No</td><td rowspan="1" colspan="1">24 (63.2)</td><td rowspan="1" colspan="1">24 (72.7)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;Fibrosis, mild</td><td rowspan="1" colspan="1">9 (23.7)</td><td rowspan="1" colspan="1">9 (27.2)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;Missing</td><td rowspan="1" colspan="1">5 (13.2)</td><td rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td colspan="3" rowspan="1">
<bold>Pathological assessment, features of pancreatitis or other inflammatory changes&#x02020;</bold>
</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;No</td><td rowspan="1" colspan="1">25 (65.8)</td><td rowspan="1" colspan="1">25 (75.8)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;Yes</td><td rowspan="1" colspan="1">4 (10.5)</td><td rowspan="1" colspan="1">4 (12.1)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;Missing</td><td rowspan="1" colspan="1">9 (23.7)</td><td rowspan="1" colspan="1">4 (12.1)</td></tr></tbody></table><table-wrap-foot><fn id="tblfn2"><p>Values are <italic toggle="yes">n</italic> (%) unless otherwise indicated. *Comparison between the pancreatic neck transection site (the stereotactic body radiotherapy target area) and the uncinate process. &#x02020;Comparison between the sample from the resection margin (the irradiated sample) and the sample from the uncinate process (the non-irradiated sample). SBRT, stereotactic body radiotherapy; EUS, endoscopic ultrasound; i.q.r., interquartile range.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="znae327-T3"><label>Table 3</label><caption><p>Clinical outcomes</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">All patients (<italic toggle="yes">n</italic> = 38)</th><th align="center" rowspan="1" colspan="1">Per-protocol (<italic toggle="yes">n</italic> = 33)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Grade B/C POPF</td><td rowspan="1" colspan="1">22 (57.9)</td><td rowspan="1" colspan="1">19 (57.6)</td></tr><tr><td rowspan="1" colspan="1">Duration of drainage (days), median (i.q.r.)</td><td rowspan="1" colspan="1">34 (17&#x02013;53)</td><td rowspan="1" colspan="1">34 (19&#x02013;52)</td></tr><tr><td rowspan="1" colspan="1">Duration of hospital stay (days), median (i.q.r.)</td><td rowspan="1" colspan="1">8 (14&#x02013;26)</td><td rowspan="1" colspan="1">8 (14&#x02013;23)</td></tr><tr><td rowspan="1" colspan="1">Reoperation</td><td rowspan="1" colspan="1">4 (10.5)</td><td rowspan="1" colspan="1">3 (9)</td></tr><tr><td rowspan="1" colspan="1">Grade B/C DGE</td><td rowspan="1" colspan="1">13 (34.2)</td><td rowspan="1" colspan="1">12 (36.4)</td></tr><tr><td rowspan="1" colspan="1">Grade B/C PPH</td><td rowspan="1" colspan="1">4 (10.5)</td><td rowspan="1" colspan="1">4 (12)</td></tr><tr><td rowspan="1" colspan="1">Grade B/C BL</td><td rowspan="1" colspan="1">4 (10.5)</td><td rowspan="1" colspan="1">3 (9.1)</td></tr><tr><td rowspan="1" colspan="1">Pancreatitis</td><td rowspan="1" colspan="1">1 (2.6)</td><td rowspan="1" colspan="1">1 (3.0)</td></tr><tr><td rowspan="1" colspan="1">Readmission</td><td rowspan="1" colspan="1">8 (21.2)</td><td rowspan="1" colspan="1">8 (24.2)</td></tr><tr><td rowspan="1" colspan="1">30-day/in-hospital mortality</td><td rowspan="1" colspan="1">1 (2.6)</td><td rowspan="1" colspan="1">1 (3)</td></tr><tr><td rowspan="1" colspan="1">90-day mortality</td><td rowspan="1" colspan="1">1 (2.6)</td><td rowspan="1" colspan="1">1 (3)</td></tr><tr><td rowspan="1" colspan="1">HbA1C (mmol/mol), median</td><td rowspan="1" colspan="1">47.1</td><td rowspan="1" colspan="1">47.8</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Missing, <italic toggle="yes">n</italic></td><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">18</td></tr><tr><td rowspan="1" colspan="1">New-onset diabetes</td><td rowspan="1" colspan="1">5 (13.2)</td><td rowspan="1" colspan="1">5 (15.2)</td></tr><tr><td colspan="3" rowspan="1">
<bold>Pancreatic insufficiency, faecal elastase measurement, <italic toggle="yes">n</italic></bold>
</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;No (&#x0003e;200&#x02005;&#x003bc;g/g)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;Mild&#x02013;moderate (100&#x02013;200&#x02005;&#x003bc;g/g)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;Severe (&#x0003c;100&#x02005;&#x003bc;g/g)</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">8</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;Missing</td><td rowspan="1" colspan="1">28</td><td rowspan="1" colspan="1">25</td></tr></tbody></table><table-wrap-foot><fn id="tblfn3"><p>POPF, postoperative pancreatic fistula; i.q.r., interquartile range; DGE, delayed gastric emptying; PPH, post-pancreatectomy haemorrhage; BL, bile leakage.</p></fn></table-wrap-foot></table-wrap></sec><sec id="znae327-s3.2"><title>Adverse events related to the study intervention</title><p>The safety cut-off of less than or equal to 15% was met; 1 (2.6%) of the 38 included patients experienced grade 3&#x02013;5 toxicity related to the intervention. This patient, as mentioned earlier, developed grade 3 toxicity because of acute pancreatitis after EUS-guided fiducial marker placement (<italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Table S1</xref></italic>). No other adverse events occurred after fiducial marker placement. After SBRT, ten patients (27%) experienced grade 1 complaints, such as fatigue (2 patients), nausea (2 patients), and abdominal pain (3 patients). These were self-limiting events without the need for medical intervention. One patient (2%) experienced grade 2 abdominal pain and required pain medication (<italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Table S2</xref></italic>). Another patient (2%) was diagnosed with asymptomatic colitis using preoperative CT, for which a hemicolectomy was indicated. The latter serious adverse event was deemed to be unrelated to SBRT, as the inflamed area was outside of the irradiated field. In one patient, the postoperative pathology revealed pancreatic ductal adenocarcinoma and the patient started chemotherapy directly after surgery.</p></sec><sec id="znae327-s3.3"><title>Effect of stereotactic body radiotherapy on firmness and fibrosis</title><p>Feasibility was met; in the 33 patients who completed the study protocol, the pancreatic tissue at the irradiated resection site was significantly more firm, according to durometric measurement, compared with the non-irradiated tissue at the uncinate process (median of 47 (i.q.r. 36&#x02013;57) <italic toggle="yes">versus</italic> 37 (i.q.r. 30&#x02013;41) Shore OO units; <italic toggle="yes">P</italic> &#x0003c; 0.001) (<italic toggle="yes"><xref rid="znae327-F3" ref-type="fig">Fig. 3</xref></italic> and <italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Table S3</xref></italic>). Shore OO units range from 0 (soft) to 100 (firm). The macroscopic assessment of the surgeon and pathologist could not distinguish between irradiated and non-irradiated tissue. In 28 patients (84.9%), as subjectively assessed by the surgeon, SBRT did not induce local firmness at the irradiated field; however, in 5 patients (15.1%), increased firmness was considered present. The pathologist assessed that, in 24 patients (72.2%), fibrosis was not present in the sample of the irradiated tissue. Microscopic assessment showed that the density of the collagen marker picrosirius red was significantly higher in the irradiated sample compared with the non-irradiated sample (median density of 6.1% (i.q.r. 4.4%&#x02013;9.5%) <italic toggle="yes">versus</italic> 4.6% (i.q.r. 2.5%&#x02013;7.4%); <italic toggle="yes">P</italic> = 0.003) (<italic toggle="yes"><xref rid="znae327-F3" ref-type="fig">Fig. 3</xref></italic> and <italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Table S3</xref></italic>). In four patients (12.1%), a small focus of pancreatitis was found in the irradiated sample, with the absence of pancreatitis in the non-irradiated sample (<italic toggle="yes"><xref rid="znae327-T2" ref-type="table">Table 2</xref></italic>).</p><fig position="float" id="znae327-F3" fig-type="figure"><label>Fig. 3</label><caption><p>Outcomes of assessments of firmness (measured using a durometer) and fibrosis (collagen density; measured using picrosirius red staining) of the resection margin (the irradiated sample) and the uncinate process (the non-irradiated sample)</p><p>An asterisk indicates statistical significance (<italic toggle="yes">P</italic> &#x0003c; 0.050).</p></caption><graphic xlink:href="znae327f3" position="float"/></fig><p>Durometric measurement and picrosirius red staining were also performed on collected samples of control patients (that is eligible patients who did not undergo SBRT). Durometric measurement in this control group revealed no significant difference in firmness between the resection site and the uncinate process (7 control patients; median of 40 (i.q.r. 35&#x02013;56) <italic toggle="yes">versus</italic> 43 (i.q.r. 34&#x02013;49) Shore OO units respectively; <italic toggle="yes">P</italic> = 0.58); likewise, the density of collagen was similar (3 control patients; median density of 12.2% (i.q.r. 8.1%&#x02013;28.6%) <italic toggle="yes">versus</italic> 12.1% (i.q.r. 9.0%&#x02013;16.1%) respectively; <italic toggle="yes">P</italic> = 0.75) (<italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Table S3</xref></italic>).</p></sec><sec id="znae327-s3.4"><title>Clinical outcomes</title><p>In the per-protocol analysis of 33 patients, 19 patients (57.6% (95% c.i. 41% to 74%)) developed a grade B/C POPF. One of these patients (3.0%) died of sepsis due to multiple intra-abdominal abscesses and bleeding of a pseudoaneurysm of the common hepatic artery. All patients with a grade B/C POPF underwent radiological percutaneous drainage with a median duration of drainage of 34 (i.q.r. 19&#x02013;52) days. PPH occurred in three patients (9.1%) with a grade B/C POPF and one patient (3.0%) without a grade B/C POPF. Among all patients included in the per-protocol analysis, the median duration of hospital stay was 8 (i.q.r. 14&#x02013;23) days, and, in three patients (9%), a reoperation was performed (<italic toggle="yes"><xref rid="znae327-T3" ref-type="table">Table 3</xref></italic>).</p></sec><sec id="znae327-s3.5"><title>Risk of postoperative pancreatic fistula in audit controls</title><p>The risk of a grade B/C POPF in audit controls, that is eligible non-study patients, during the study interval, was 34% (45 of 134 audit controls; 95% c.i. 27% to 42%), compared with 57.6% (95% c.i. 41% to 74%) in the study population (<italic toggle="yes">P</italic> = 0.011). Potential risk factors for POPF in audit controls are shown in <italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Table S4</xref></italic>.</p></sec><sec id="znae327-s3.6"><title>Exocrine and endocrine pancreatic function</title><p>After pancreatoduodenectomy, 5 of 38 patients (13.2%) were diagnosed with new-onset diabetes and 31 of 38 patients (81.5%) received pancreatic enzyme replacement therapy. Faecal elastase was measured in 10 of 38 patients (26.3%), who all exhibited severe pancreatic insufficiency.</p></sec></sec><sec sec-type="discussion" id="znae327-s4"><title>Discussion</title><p>This prospective multicentre open-label phase II single-arm trial demonstrates that a single fraction of 12&#x02005;Gy SBRT at the future pancreatic neck transection site in patients undergoing high-risk pancreatoduodenectomy is safe, is feasible (as it increases firmness, according to durometric measurement), and induces pancreatic fibrosis. However, no efficacy could be demonstrated, as SBRT appears ineffective in reducing the rate of grade B/C POPF after pancreatoduodenectomy compared with audit controls.</p><p>These results cannot be compared with other studies, as this is the first study to assess SBRT with regard to preventing POPF after pancreatoduodenectomy in patients with diagnoses other than pancreatic ductal adenocarcinoma. In the study population, 19 patients (57.6% (95% c.i. 41% to 74%)) developed a grade B/C POPF. During the study interval, the population risk in audit controls was 34% (95% c.i. 27% to 42%). Therefore, the authors cannot exclude the possibility that the intervention induced changes that increased the risk of POPF. The association between POPF and radiotherapy has been predominantly noted in patients with pancreatic ductal adenocarcinoma in the pancreatic head, where obstruction of the MPD leads to pancreatic inflammation and fibrosis<sup><xref rid="znae327-B28" ref-type="bibr">28</xref></sup>. The present study included patients undergoing pancreatoduodenectomy with &#x02018;healthy&#x02019; pancreatic tissue. In these patients, a single fraction of SBRT may have caused changes that rendered the tissue more fragile or prone to anastomotic dehiscence. However, surgeons reported no detectable changes in the irradiated tissue in most patients (84.8%) and inflammatory alterations at the resection margin were only observed in four patients (10.5%), without reported difficulties in pancreatic dissection. Without a control group, it is difficult to determine whether the increased POPF rate is directly attributable to SBRT or reflects other patient- or procedure-related factors. Notably, similar to the high POPF rate observed in the present study, a recent prospective study involving 566 high-risk patients reported a POPF rate of 39% after pancreatoduodenectomy<sup><xref rid="znae327-B29" ref-type="bibr">29</xref></sup>. This highlights the significant risk of POPF within this population and underscores the need for effective interventions.</p><p>The study intervention resulted in minimal and mild side effects, achieving the safety outcomes. However, one patient, diagnosed with an ampullary adenoma, developed pancreatitis post-EUS-guided fiducial marker placement. Consequently, the patient did not receive SBRT but ultimately underwent pancreatoduodenectomy after recovery from pancreatitis. The potential harm of the study intervention includes impaired exocrine or endocrine pancreatic function. However, the authors do not expect a single fraction of SBRT on a small part of the pancreas to have further impaired endocrine/exocrine function beyond the impact of pancreatoduodenectomy. New-onset diabetes was diagnosed in 13.2% of the patients after pancreatoduodenectomy, which is comparable to the pooled estimate of 16% reported in a recent meta-analysis<sup><xref rid="znae327-B30" ref-type="bibr">30</xref></sup>. Concerning pancreatic function, up to 74% (range 36%&#x02013;100%) of patients develop exocrine insufficiency after pancreatic surgery, necessitating enzyme replacement therapy<sup><xref rid="znae327-B31" ref-type="bibr">31</xref></sup>, which is similar to the 81.5% of patients in the present study.</p><p>As mentioned, FIBROPANC is the first trial to investigate the potential of a single SBRT fraction of 12&#x02005;Gy to reduce the risk of postoperative complications in high-risk patients. Over the past years, compelling evidence has demonstrated that preoperative chemoradiotherapy reduces the rate of POPF after pancreatoduodenectomy in patients with pancreatic ductal adenocarcinoma<sup><xref rid="znae327-B8" ref-type="bibr">8&#x02013;10</xref></sup>. PREOPANC was the first RCT to report lower rates of POPF in patients with pancreatic cancer after preoperative chemoradiotherapy compared with immediate surgery (0.0% <italic toggle="yes">versus</italic> 9.2%; <italic toggle="yes">P</italic> = 0.011)<sup><xref rid="znae327-B9" ref-type="bibr">9</xref></sup>. Although preoperative chemoradiotherapy is associated with a reduced rate of POPF, a single fraction of SBRT in the present study appeared ineffective in this high-risk study population. The increased firmness (measured using a durometer) and fibrosis was insufficient to reduce the rate of POPF. Several factors could potentially explain this. A time&#x02013;effect relationship between the post-radiation interval and pancreatic fibrosis may be present. The late fibroproliferative phase, characterized by tissue reorganization and accumulation of extracellular matrix proteins, typically occurs after several months<sup><xref rid="znae327-B32" ref-type="bibr">32</xref></sup>. For this reason, further postponing surgery could be beneficial, as this allows the pancreatic tissue more time to modulate. However, in the present study, in patients with an interval between SBRT and surgery of greater than 6 weeks, the rate of grade B/C POPF was 53%. Further, a single fraction of 12&#x02005;Gy (Equivalent Dose in 2 Gray Fractions [EQD2Gy] = 36&#x02005;Gy, &#x003b1;/&#x003b2; = 3&#x02005;Gy) monotherapy may not be sufficient to induce the fibrosis necessary to reduce the risk of POPF. In previous studies, radiotherapy was combined with chemotherapy, working as a radiosensitizer, and was provided in multiple fractions. The current dose of 12&#x02005;Gy was calculated based on the PREOPANC trial (15 &#x000d7; 2.4&#x02005;Gy, EQD2Gy&#x0223c;38&#x02005;Gy), but was reduced to a single fraction to minimize patient burden and time delay to operation<sup><xref rid="znae327-B9" ref-type="bibr">9</xref></sup>. The authors presumed that the late effect rather than the acute effect of radiotherapy was responsible for the accumulation of fibrosis. Therefore, the regimen of 1 &#x000d7; 12&#x02005;Gy corresponded to a biological equivalent dose for the late effect in the PREOPANC trial, but to a lower biological equivalent dose of 26&#x02005;Gy<sub>10</sub> for acute effects. The latter may contribute to the observed inefficacy of the current regimen.</p><p>The association between preoperative chemoradiotherapy and the rate of POPF may be explained by the prolonged time to surgery, rather than the chemoradiotherapy itself. In most patients with a pancreatic ductal adenocarcinoma located in the head, the interval of MDP obstruction is prolonged by postponing the surgery in the preoperative setting, which could result in a firmer pancreatic texture<sup><xref rid="znae327-B28" ref-type="bibr">28</xref></sup>. The randomized PREOPANC-2 trial (neoadjuvant chemoradiotherapy <italic toggle="yes">versus</italic> neoadjuvant chemotherapy) and randomized PREOPANC-3 trial (immediate surgery <italic toggle="yes">versus</italic> perioperative chemotherapy) expect to provide definite answers on the impact of preoperative therapy on POPF<sup><xref rid="znae327-B33" ref-type="bibr">33</xref>,<xref rid="znae327-B34" ref-type="bibr">34</xref></sup>.</p><p>The population risk of POPF before the start of the study (2014&#x02013;2018) was 27.5% and increased to 35.6% (47 of 134, 95% c.i. 32% to 40%) during the study interval<sup><xref rid="znae327-B20" ref-type="bibr">20</xref></sup>. The increase in the rate of POPF during the study interval, both in the audit controls and in the study patients, is partly explained by the implementation of the nationwide PORSCH trial<sup><xref rid="znae327-B6" ref-type="bibr">6</xref></sup>. This trial recommended radiological drainage at a low threshold, which, by definition, results in a grade B POPF.</p><p>As pancreatic texture is the most critical risk factor for POPF, multiple studies have investigated methods to assess pancreatic texture<sup><xref rid="znae327-B17" ref-type="bibr">17&#x02013;19</xref></sup>. It has been reported that using a durometer allows a surgeon to successfully distinguish between a non-pathological soft pancreas and a hard pancreas<sup><xref rid="znae327-B19" ref-type="bibr">19</xref></sup>. FIBROPANC is the first trial to objectively assess radiation-induced firmness using a durometer in a standardized way and radiation-induced fibrosis by computational collagen quantification using picrosirius red staining. The durometer and collagen quantification using picrosirius red staining discriminated between irradiated and non-irradiated tissue, whereas the surgeon did not observe these differences. The absence of differences in firmness and fibrosis between the resection site and the uncinate process in control patients increased the validity of these measurements. Therefore, using a durometer using a standardized method and collagen quantification using picrosirius red staining is valid for assessing firmness and pancreatic fibrosis in future clinical trials.</p><p>The findings of this study should be interpreted considering limitations. Due to the small sample size and single-arm non-randomized design, drawing definitive conclusions regarding the potential positive or negative impact of the intervention on POPF is challenging. Based on the observed POPF rate, the authors anticipate that a randomized trial will not be able to demonstrate the efficacy of SBRT in this population. It may be worthwhile to explore whether extending the time frame between SBRT and surgery might allow for more fibrosis to accumulate, as discussed previously. Also, administering a higher biological equivalent dose for acute effects (for example 3 fractions of 8&#x02005;Gy each) may induce fibrosis more extensively. Exposing patients to the potential risks associated with these interventions could be justified based on the outcomes of the present trial. Total pancreatectomy has been proposed as an alternative to high-risk pancreatoduodenectomy to avoid POPF<sup><xref rid="znae327-B29" ref-type="bibr">29</xref>,<xref rid="znae327-B35" ref-type="bibr">35</xref></sup>. As total pancreatectomy results in complete endocrine and exocrine insufficiency, this approach should only be considered as a last resort. Further trials should focus on combining effective interventions to prevent POPF in a multicentre RCT.</p></sec><sec id="znae327-s5"><title>Collaborators</title><p>The FIBROPANC trial was conducted on behalf of the Dutch Pancreatic Cancer Group. Other collaborator: Annalisa Comandatore (General Surgery Unit, Cisanello Hospital, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy).</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sup1" position="float" content-type="local-data"><label>znae327_Supplementary_Data</label><media xlink:href="znae327_supplementary_data.docx"/></supplementary-material></sec></body><back><ack id="ack1"><title>Acknowledgements</title><p>L.V.W. and T.E.H. share first authorship and G.v.T., C.H.v.E., and M.G.B. share senior authorship. The authors thank all patients who participated in the FIBROPANC trial and would like to thank Mahesh Algoe, Elise van der Oost, and Disha Vadgama for their assistance with durometric measurement.</p></ack><sec id="znae327-s6"><title>Funding</title><p>The authors have no funding to declare.</p></sec><sec id="znae327-s7"><title>Disclosure</title><p>The authors declare no conflict of interest.</p></sec><sec id="znae327-s8"><title>Supplementary material</title><p>
<xref rid="sup1" ref-type="supplementary-material">Supplementary material</xref> is available at <italic toggle="yes">BJS</italic> online.</p></sec><sec sec-type="data-availability" id="znae327-s9"><title>Data availability</title><p>Data are available from the corresponding author upon reasonable request.</p></sec><ref-list id="ref1"><title>References</title><ref id="znae327-B1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wang</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Ma</surname><given-names>R</given-names></string-name>, <string-name><surname>Churilov</surname><given-names>L</given-names></string-name>, <string-name><surname>Eleftheriou</surname><given-names>P</given-names></string-name>, <string-name><surname>Nikfarjam</surname><given-names>M</given-names></string-name>, <string-name><surname>Christophi</surname><given-names>C</given-names></string-name><etal>et al</etal></person-group>
<article-title>The cost of perioperative complications following pancreaticoduodenectomy: a systematic review</article-title>. <source>Pancreatology</source><year>2018</year>;<volume>18</volume>:<fpage>208</fpage>&#x02013;<lpage>220</lpage><pub-id pub-id-type="pmid">29331217</pub-id>
</mixed-citation></ref><ref id="znae327-B2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bassi</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Marchegiani</surname><given-names>G</given-names></string-name>, <string-name><surname>Dervenis</surname><given-names>C</given-names></string-name>, <string-name><surname>Sarr</surname><given-names>M</given-names></string-name>, <string-name><surname>Abu Hilal</surname><given-names>M</given-names></string-name>, <string-name><surname>Adham</surname><given-names>M</given-names></string-name><etal>et al</etal></person-group>
<article-title>The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after</article-title>. <source>Surgery</source><year>2017</year>;<volume>161</volume>:<fpage>584</fpage>&#x02013;<lpage>591</lpage><pub-id pub-id-type="pmid">28040257</pub-id>
</mixed-citation></ref><ref id="znae327-B3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mackay</surname>
<given-names>TM</given-names>
</string-name>, <string-name><surname>Wellner</surname><given-names>UF</given-names></string-name>, <string-name><surname>van Rijssen</surname><given-names>LB</given-names></string-name>, <string-name><surname>Stoop</surname><given-names>TF</given-names></string-name>, <string-name><surname>Busch</surname><given-names>OR</given-names></string-name>, <string-name><surname>Groot Koerkamp</surname><given-names>B</given-names></string-name><etal>et al</etal></person-group>
<article-title>Variation in pancreatoduodenectomy as delivered in two national audits</article-title>. <source>Br J Surg</source><year>2019</year>;<volume>106</volume>:<fpage>747</fpage>&#x02013;<lpage>755</lpage><pub-id pub-id-type="pmid">30706456</pub-id>
</mixed-citation></ref><ref id="znae327-B4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ma</surname>
<given-names>LW</given-names>
</string-name>, <string-name><surname>Dominguez-Rosado</surname><given-names>I</given-names></string-name>, <string-name><surname>Gennarelli</surname><given-names>RL</given-names></string-name>, <string-name><surname>Bach</surname><given-names>PB</given-names></string-name>, <string-name><surname>Gonen</surname><given-names>M</given-names></string-name>, <string-name><surname>D'Angelica</surname><given-names>MI</given-names></string-name><etal>et al</etal></person-group>
<article-title>The cost of postoperative pancreatic fistula versus the cost of pasireotide: results from a prospective randomized trial</article-title>. <source>Ann Surg</source><year>2017</year>;<volume>265</volume>:<fpage>11</fpage>&#x02013;<lpage>16</lpage><pub-id pub-id-type="pmid">27429029</pub-id>
</mixed-citation></ref><ref id="znae327-B5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Jajja</surname>
<given-names>MR</given-names>
</string-name>, <string-name><surname>Mustansir</surname><given-names>F</given-names></string-name>, <string-name><surname>Nadeem</surname><given-names>SO</given-names></string-name>, <string-name><surname>Lovasik</surname><given-names>BP</given-names></string-name>, <string-name><surname>Blair</surname><given-names>CM</given-names></string-name>, <string-name><surname>Sarmiento</surname><given-names>JM</given-names></string-name></person-group>. <article-title>Counting the cost: financial implications of complications following pancreaticoduodenectomy</article-title>. <source>HPB (Oxford)</source><year>2022</year>;<volume>24</volume>:<fpage>1177</fpage>&#x02013;<lpage>1185</lpage><pub-id pub-id-type="pmid">35078715</pub-id>
</mixed-citation></ref><ref id="znae327-B6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Smits</surname>
<given-names>FJ</given-names>
</string-name>, <string-name><surname>Henry</surname><given-names>AC</given-names></string-name>, <string-name><surname>Besselink</surname><given-names>MG</given-names></string-name>, <string-name><surname>Busch</surname><given-names>OR</given-names></string-name>, <string-name><surname>van Eijck</surname><given-names>CH</given-names></string-name>, <string-name><surname>Arntz</surname><given-names>M</given-names></string-name><etal>et al</etal></person-group>
<article-title>Algorithm-based care versus usual care for the early recognition and management of complications after pancreatic resection in the Netherlands: an open-label, nationwide, stepped-wedge cluster-randomised trial</article-title>. <source>Lancet</source><year>2022</year>;<volume>399</volume>:<fpage>1867</fpage>&#x02013;<lpage>1875</lpage><pub-id pub-id-type="pmid">35490691</pub-id>
</mixed-citation></ref><ref id="znae327-B7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Suurmeijer</surname>
<given-names>JA</given-names>
</string-name>, <string-name><surname>Henry</surname><given-names>AC</given-names></string-name>, <string-name><surname>Bonsing</surname><given-names>BA</given-names></string-name>, <string-name><surname>Bosscha</surname><given-names>K</given-names></string-name>, <string-name><surname>van Dam</surname><given-names>RM</given-names></string-name>, <string-name><surname>van Eijck</surname><given-names>CH</given-names></string-name><etal>et al</etal></person-group>
<article-title>Outcome of pancreatic surgery during the first six years of a mandatory audit within the Dutch Pancreatic Cancer Group</article-title>. <source>Ann Surg</source><year>2023</year>;<volume>278</volume>:<fpage>260</fpage>&#x02013;<lpage>266</lpage><pub-id pub-id-type="pmid">35866656</pub-id>
</mixed-citation></ref><ref id="znae327-B8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>van Dongen</surname>
<given-names>JC</given-names>
</string-name>, <string-name><surname>Wismans</surname><given-names>LV</given-names></string-name>, <string-name><surname>Suurmeijer</surname><given-names>JA</given-names></string-name>, <string-name><surname>Besselink</surname><given-names>MG</given-names></string-name>, <string-name><surname>de Wilde</surname><given-names>RF</given-names></string-name>, <string-name><surname>Groot Koerkamp</surname><given-names>B</given-names></string-name><etal>et al</etal></person-group>
<article-title>The effect of preoperative chemotherapy and chemoradiotherapy on pancreatic fistula and other surgical complications after pancreatic resection: a systematic review and meta-analysis of comparative studies</article-title>. <source>HPB (Oxford)</source><year>2021</year>;<volume>23</volume>:<fpage>1321</fpage>&#x02013;<lpage>1331</lpage><pub-id pub-id-type="pmid">34099372</pub-id>
</mixed-citation></ref><ref id="znae327-B9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>van Dongen</surname>
<given-names>JC</given-names>
</string-name>, <string-name><surname>Suker</surname><given-names>M</given-names></string-name>, <string-name><surname>Versteijne</surname><given-names>E</given-names></string-name>, <string-name><surname>Bonsing</surname><given-names>BA</given-names></string-name>, <string-name><surname>Mieog</surname><given-names>JSD</given-names></string-name>, <string-name><surname>de Vos-Geelen</surname><given-names>J</given-names></string-name><etal>et al</etal></person-group>
<article-title>Surgical complications in a multicenter randomized trial comparing preoperative chemoradiotherapy and immediate surgery in patients with resectable and borderline resectable pancreatic cancer (PREOPANC trial)</article-title>. <source>Ann Surg</source><year>2022</year>;<volume>275</volume>:<fpage>979</fpage>&#x02013;<lpage>984</lpage><pub-id pub-id-type="pmid">33201120</pub-id>
</mixed-citation></ref><ref id="znae327-B10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wismans</surname>
<given-names>LV</given-names>
</string-name>, <string-name><surname>Suurmeijer</surname><given-names>JA</given-names></string-name>, <string-name><surname>van Dongen</surname><given-names>JC</given-names></string-name>, <string-name><surname>Bonsing</surname><given-names>BA</given-names></string-name>, <string-name><surname>Van Santvoort</surname><given-names>HC</given-names></string-name>, <string-name><surname>Wilmink</surname><given-names>JW</given-names></string-name><etal>et al</etal></person-group>
<article-title>Preoperative chemoradiotherapy but not chemotherapy is associated with reduced risk of postoperative pancreatic fistula after pancreatoduodenectomy for pancreatic ductal adenocarcinoma: a nationwide analysis</article-title>. <source>Surgery</source><year>2024</year>;<volume>175</volume>:<fpage>1580</fpage>&#x02013;<lpage>1586</lpage><pub-id pub-id-type="pmid">38448277</pub-id>
</mixed-citation></ref><ref id="znae327-B11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gemici</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Sargin</surname><given-names>M</given-names></string-name>, <string-name><surname>Uygur-Bayramicli</surname><given-names>O</given-names></string-name>, <string-name><surname>Mayadagli</surname><given-names>A</given-names></string-name>, <string-name><surname>Yaprak</surname><given-names>G</given-names></string-name>, <string-name><surname>Dabak</surname><given-names>R</given-names></string-name><etal>et al</etal></person-group>
<article-title>Risk of endocrine pancreatic insufficiency in patients receiving adjuvant chemoradiation for resected gastric cancer</article-title>. <source>Radiother Oncol</source><year>2013</year>;<volume>107</volume>:<fpage>195</fpage>&#x02013;<lpage>199</lpage><pub-id pub-id-type="pmid">23647754</pub-id>
</mixed-citation></ref><ref id="znae327-B12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wydmanski</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Polanowski</surname><given-names>P</given-names></string-name>, <string-name><surname>Tukiendorf</surname><given-names>A</given-names></string-name>, <string-name><surname>Maslyk</surname><given-names>B</given-names></string-name></person-group>. <article-title>Radiation-induced injury of the exocrine pancreas after chemoradiotherapy for gastric cancer</article-title>. <source>Radiother Oncol</source><year>2016</year>;<volume>118</volume>:<fpage>535</fpage>&#x02013;<lpage>539</lpage><pub-id pub-id-type="pmid">26709067</pub-id>
</mixed-citation></ref><ref id="znae327-B13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mungroop</surname>
<given-names>TH</given-names>
</string-name>, <string-name><surname>Klompmaker</surname><given-names>S</given-names></string-name>, <string-name><surname>Wellner</surname><given-names>UF</given-names></string-name>, <string-name><surname>Steyerberg</surname><given-names>EW</given-names></string-name>, <string-name><surname>Coratti</surname><given-names>A</given-names></string-name>, <string-name><surname>D&#x02019;Hondt</surname><given-names>M</given-names></string-name><etal>et al</etal></person-group>
<article-title>Updated alternative Fistula Risk Score (ua-FRS) to include minimally invasive pancreatoduodenectomy: pan-European validation</article-title>. <source>Ann Surg</source><year>2021</year>;<volume>273</volume>:<fpage>334</fpage>&#x02013;<lpage>340</lpage><pub-id pub-id-type="pmid">30829699</pub-id>
</mixed-citation></ref><ref id="znae327-B14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>van Dongen</surname>
<given-names>JC</given-names>
</string-name>, <string-name><surname>van Dam</surname><given-names>JL</given-names></string-name>, <string-name><surname>Besselink</surname><given-names>MG</given-names></string-name>, <string-name><surname>Bonsing</surname><given-names>BA</given-names></string-name>, <string-name><surname>Bosscha</surname><given-names>K</given-names></string-name>, <string-name><surname>Busch</surname><given-names>OR</given-names></string-name><etal>et al</etal></person-group>
<article-title>Fistula risk score for auditing pancreatoduodenectomy: the auditing-FRS</article-title>. <source>Ann Surg</source><year>2023</year>;<volume>278</volume>:<fpage>e272</fpage>&#x02013;<lpage>e277</lpage><pub-id pub-id-type="pmid">35837978</pub-id>
</mixed-citation></ref><ref id="znae327-B15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Schuh</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>Mihaljevic</surname><given-names>AL</given-names></string-name>, <string-name><surname>Probst</surname><given-names>P</given-names></string-name>, <string-name><surname>Trudeau</surname><given-names>MT</given-names></string-name>, <string-name><surname>M&#x000fc;ller</surname><given-names>PC</given-names></string-name>, <string-name><surname>Marchegiani</surname><given-names>G</given-names></string-name><etal>et al</etal></person-group>
<article-title>A simple classification of pancreatic duct size and texture predicts postoperative pancreatic fistula: a classification of the International Study Group of Pancreatic Surgery</article-title>. <source>Ann Surg</source><year>2023</year>;<volume>277</volume>:<fpage>e597</fpage>&#x02013;<lpage>e608</lpage><pub-id pub-id-type="pmid">33914473</pub-id>
</mixed-citation></ref><ref id="znae327-B16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Theijse</surname>
<given-names>RT</given-names>
</string-name>, <string-name><surname>Stoop</surname><given-names>TF</given-names></string-name>, <string-name><surname>Hendriks</surname><given-names>TE</given-names></string-name>, <string-name><surname>Suurmeijer</surname><given-names>JA</given-names></string-name>, <string-name><surname>Smits</surname><given-names>FJ</given-names></string-name>, <string-name><surname>Bonsing</surname><given-names>BA</given-names></string-name><etal>et al</etal></person-group>
<article-title>Nationwide outcome after pancreatoduodenectomy in patients at very high risk (ISGPS-D) for postoperative pancreatic fistula</article-title>. <source>Ann Surg</source><year>2023</year>; DOI: <pub-id pub-id-type="doi">10.1097/SLA.000000000000174</pub-id> [Epub ahead of print]</mixed-citation></ref><ref id="znae327-B17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Belyaev</surname>
<given-names>O</given-names>
</string-name>, <string-name><surname>Herden</surname><given-names>H</given-names></string-name>, <string-name><surname>Meier</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Muller</surname><given-names>CA</given-names></string-name>, <string-name><surname>Seelig</surname><given-names>MH</given-names></string-name>, <string-name><surname>Herzog</surname><given-names>T</given-names></string-name><etal>et al</etal></person-group>
<article-title>Assessment of pancreatic hardness&#x02014;surgeon versus durometer</article-title>. <source>J Surg Res</source><year>2010</year>;<volume>158</volume>:<fpage>53</fpage>&#x02013;<lpage>60</lpage><pub-id pub-id-type="pmid">19394646</pub-id>
</mixed-citation></ref><ref id="znae327-B18"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Marchegiani</surname>
<given-names>G</given-names>
</string-name>, <string-name><surname>Ballarin</surname><given-names>R</given-names></string-name>, <string-name><surname>Malleo</surname><given-names>G</given-names></string-name>, <string-name><surname>Andrianello</surname><given-names>S</given-names></string-name>, <string-name><surname>Allegrini</surname><given-names>V</given-names></string-name>, <string-name><surname>Pulvirenti</surname><given-names>A</given-names></string-name><etal>et al</etal></person-group>
<article-title>Quantitative assessment of pancreatic texture using a durometer: a new tool to predict the risk of developing a postoperative fistula</article-title>. <source>World J Surg</source><year>2017</year>;<volume>41</volume>:<fpage>2876</fpage>&#x02013;<lpage>2883</lpage><pub-id pub-id-type="pmid">28608016</pub-id>
</mixed-citation></ref><ref id="znae327-B19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hong</surname>
<given-names>TH</given-names>
</string-name>, <string-name><surname>Choi</surname><given-names>J-I</given-names></string-name>, <string-name><surname>Park</surname><given-names>MY</given-names></string-name>, <string-name><surname>Rha</surname><given-names>SE</given-names></string-name>, <string-name><surname>Lee</surname><given-names>YJ</given-names></string-name>, <string-name><surname>You</surname><given-names>YK</given-names></string-name><etal>et al</etal></person-group>
<article-title>Pancreatic hardness: correlation of surgeon&#x02019;s palpation, durometer measurement and preoperative magnetic resonance imaging features</article-title>. <source>World J Gastroenterol</source><year>2017</year>;<volume>23</volume>:<fpage>2044</fpage>&#x02013;<lpage>2051</lpage><pub-id pub-id-type="pmid">28373771</pub-id>
</mixed-citation></ref><ref id="znae327-B20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Suurmeijer</surname>
<given-names>JA</given-names>
</string-name>, <string-name><surname>Wismans</surname><given-names>LV</given-names></string-name>, <string-name><surname>Hendriks</surname><given-names>TE</given-names></string-name>, <string-name><surname>Bruynzeel</surname><given-names>AM</given-names></string-name>, <string-name><surname>Nuyttens</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Intven</surname><given-names>MPW</given-names></string-name><etal>et al</etal></person-group>
<article-title>Feasibility, safety and preliminary efficacy of preoperative stereotactic radiotherapy on the future pancreatic neck transection margin to reduce the risk of pancreatic fistula after high-risk pancreatoduodenectomy (FIBROPANC): protocol for a multicentre, single-arm trial</article-title>. <source>BMJ Open</source><year>2024</year>;<volume>14</volume>:<fpage>e087193</fpage></mixed-citation></ref><ref id="znae327-B21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Belyaev</surname>
<given-names>O</given-names>
</string-name>, <string-name><surname>Herden</surname><given-names>H</given-names></string-name>, <string-name><surname>Meier</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Muller</surname><given-names>CA</given-names></string-name>, <string-name><surname>Seelig</surname><given-names>MH</given-names></string-name>, <string-name><surname>Herzog</surname><given-names>T</given-names></string-name><etal>et al</etal></person-group>
<article-title>Assessment of pancreatic hardness-surgeon versus durometer</article-title>. <source>J Surg Res</source><year>2010</year>;<volume>158</volume>:<fpage>53</fpage>&#x02013;<lpage>60</lpage><pub-id pub-id-type="pmid">19394646</pub-id>
</mixed-citation></ref><ref id="znae327-B22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bankhead</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Loughrey</surname><given-names>MB</given-names></string-name>, <string-name><surname>Fern&#x000e1;ndez</surname><given-names>JA</given-names></string-name>, <string-name><surname>Dombrowski</surname><given-names>Y</given-names></string-name>, <string-name><surname>McArt</surname><given-names>DG</given-names></string-name>, <string-name><surname>Dunne</surname><given-names>PD</given-names></string-name><etal>et al</etal></person-group>
<article-title>QuPath: open source software for digital pathology image analysis</article-title>. <source>Sci Rep</source><year>2017</year>;<volume>7</volume>:<fpage>16878</fpage><pub-id pub-id-type="pmid">29203879</pub-id>
</mixed-citation></ref><ref id="znae327-B23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wente</surname>
<given-names>MN</given-names>
</string-name>, <string-name><surname>Veit</surname><given-names>JA</given-names></string-name>, <string-name><surname>Bassi</surname><given-names>C</given-names></string-name>, <string-name><surname>Dervenis</surname><given-names>C</given-names></string-name>, <string-name><surname>Fingerhut</surname><given-names>A</given-names></string-name>, <string-name><surname>Gouma</surname><given-names>DJ</given-names></string-name><etal>et al</etal></person-group>
<article-title>Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition</article-title>. <source>Surgery</source><year>2007</year>;<volume>142</volume>:<fpage>20</fpage>&#x02013;<lpage>25</lpage><pub-id pub-id-type="pmid">17629996</pub-id>
</mixed-citation></ref><ref id="znae327-B24"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Besselink</surname>
<given-names>MG</given-names>
</string-name>, <string-name><surname>van Rijssen</surname><given-names>LB</given-names></string-name>, <string-name><surname>Bassi</surname><given-names>C</given-names></string-name>, <string-name><surname>Dervenis</surname><given-names>C</given-names></string-name>, <string-name><surname>Montorsi</surname><given-names>M</given-names></string-name>, <string-name><surname>Adham</surname><given-names>M</given-names></string-name><etal>et al</etal></person-group>
<article-title>Definition and classification of chyle leak after pancreatic operation: a consensus statement by the International Study group on Pancreatic Surgery</article-title>. <source>Surgery</source><year>2017</year>;<volume>161</volume>:<fpage>365</fpage>&#x02013;<lpage>372</lpage><pub-id pub-id-type="pmid">27692778</pub-id>
</mixed-citation></ref><ref id="znae327-B25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Koch</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Garden</surname><given-names>OJ</given-names></string-name>, <string-name><surname>Padbury</surname><given-names>R</given-names></string-name>, <string-name><surname>Rahbari</surname><given-names>NN</given-names></string-name>, <string-name><surname>Adam</surname><given-names>R</given-names></string-name>, <string-name><surname>Capussotti</surname><given-names>L</given-names></string-name><etal>et al</etal></person-group>
<article-title>Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery</article-title>. <source>Surgery</source><year>2011</year>;<volume>149</volume>:<fpage>680</fpage>&#x02013;<lpage>688</lpage><pub-id pub-id-type="pmid">21316725</pub-id>
</mixed-citation></ref><ref id="znae327-B26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wente</surname>
<given-names>MN</given-names>
</string-name>, <string-name><surname>Bassi</surname><given-names>C</given-names></string-name>, <string-name><surname>Dervenis</surname><given-names>C</given-names></string-name>, <string-name><surname>Fingerhut</surname><given-names>A</given-names></string-name>, <string-name><surname>Gouma</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Izbicki</surname><given-names>JR</given-names></string-name><etal>et al</etal></person-group>
<article-title>Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS)</article-title>. <source>Surgery</source><year>2007</year>;<volume>142</volume>:<fpage>761</fpage>&#x02013;<lpage>768</lpage><pub-id pub-id-type="pmid">17981197</pub-id>
</mixed-citation></ref><ref id="znae327-B27"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<collab>World Medical Association</collab>
</person-group>. <article-title>World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects</article-title>. <source>JAMA</source><year>2013</year>;<volume>310</volume>:<fpage>2191</fpage>&#x02013;<lpage>2194</lpage><pub-id pub-id-type="pmid">24141714</pub-id>
</mixed-citation></ref><ref id="znae327-B28"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kl&#x000f6;ppel</surname>
<given-names>G</given-names>
</string-name>, <string-name><surname>Detlefsen</surname><given-names>S</given-names></string-name>, <string-name><surname>Feyerabend</surname><given-names>B</given-names></string-name></person-group>. <article-title>Fibrosis of the pancreas: the initial tissue damage and the resulting pattern</article-title>. <source>Virchows Arch</source><year>2004</year>;<volume>445</volume>:<fpage>1</fpage>&#x02013;<lpage>8</lpage><pub-id pub-id-type="pmid">15138818</pub-id>
</mixed-citation></ref><ref id="znae327-B29"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Marchegiani</surname>
<given-names>G</given-names>
</string-name>, <string-name><surname>Perri</surname><given-names>G</given-names></string-name>, <string-name><surname>Burelli</surname><given-names>A</given-names></string-name>, <string-name><surname>Zoccatelli</surname><given-names>F</given-names></string-name>, <string-name><surname>Andrianello</surname><given-names>S</given-names></string-name>, <string-name><surname>Luchini</surname><given-names>C</given-names></string-name><etal>et al</etal></person-group>
<article-title>High-risk pancreatic anastomosis versus total pancreatectomy after pancreatoduodenectomy: postoperative outcomes and quality of life analysis</article-title>. <source>Ann Surg</source><year>2022</year>;<volume>276</volume>:<fpage>e905</fpage>&#x02013;<lpage>e913</lpage><pub-id pub-id-type="pmid">33914471</pub-id>
</mixed-citation></ref><ref id="znae327-B30"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wu</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Nahm</surname><given-names>CB</given-names></string-name>, <string-name><surname>Jamieson</surname><given-names>NB</given-names></string-name>, <string-name><surname>Samra</surname><given-names>J</given-names></string-name>, <string-name><surname>Clifton-Bligh</surname><given-names>R</given-names></string-name>, <string-name><surname>Mittal</surname><given-names>A</given-names></string-name><etal>et al</etal></person-group>
<article-title>Risk factors for development of diabetes mellitus (type 3c) after partial pancreatectomy: a systematic review</article-title>. <source>Clin Endocrinol (Oxf)</source><year>2020</year>;<volume>92</volume>:<fpage>396</fpage>&#x02013;<lpage>406</lpage><pub-id pub-id-type="pmid">32017157</pub-id>
</mixed-citation></ref><ref id="znae327-B31"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sikkens</surname>
<given-names>ECM</given-names>
</string-name>, <string-name><surname>Cahen</surname><given-names>DL</given-names></string-name>, <string-name><surname>van Eijck</surname><given-names>C</given-names></string-name>, <string-name><surname>Kuipers</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Bruno</surname><given-names>MJ</given-names></string-name></person-group>. <article-title>The daily practice of pancreatic enzyme replacement therapy after pancreatic surgery: a northern European survey: enzyme replacement after surgery</article-title>. <source>J Gastrointest Surg</source><year>2012</year>;<volume>16</volume>:<fpage>1487</fpage>&#x02013;<lpage>1492</lpage><pub-id pub-id-type="pmid">22711213</pub-id>
</mixed-citation></ref><ref id="znae327-B32"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Fijardo</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Kwan</surname><given-names>JYY</given-names></string-name>, <string-name><surname>Bissey</surname><given-names>P-A</given-names></string-name>, <string-name><surname>Citrin</surname><given-names>DE</given-names></string-name>, <string-name><surname>Yip</surname><given-names>KW</given-names></string-name>, <string-name><surname>Liu</surname><given-names>F-F</given-names></string-name></person-group>. <article-title>The clinical manifestations and molecular pathogenesis of radiation fibrosis</article-title>. <source>EBioMedicine</source><year>2024</year>;<volume>103</volume>:<fpage>105089</fpage><pub-id pub-id-type="pmid">38579363</pub-id>
</mixed-citation></ref><ref id="znae327-B33"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>van Dam</surname>
<given-names>JL</given-names>
</string-name>, <string-name><surname>Verkolf</surname><given-names>EMM</given-names></string-name>, <string-name><surname>Dekker</surname><given-names>EN</given-names></string-name>, <string-name><surname>Bonsing</surname><given-names>BA</given-names></string-name>, <string-name><surname>Bratlie</surname><given-names>SO</given-names></string-name>, <string-name><surname>Brosens</surname><given-names>LAA</given-names></string-name><etal>et al</etal></person-group>
<article-title>Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial</article-title>. <source>BMC Cancer</source><year>2023</year>;<volume>23</volume>:<fpage>728</fpage><pub-id pub-id-type="pmid">37550634</pub-id>
</mixed-citation></ref><ref id="znae327-B34"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Janssen</surname>
<given-names>QP</given-names>
</string-name>, <string-name><surname>van Dam</surname><given-names>JL</given-names></string-name>, <string-name><surname>Bonsing</surname><given-names>BA</given-names></string-name>, <string-name><surname>Bos</surname><given-names>H</given-names></string-name>, <string-name><surname>Bosscha</surname><given-names>KP</given-names></string-name>, <string-name><surname>Coene</surname><given-names>PPLO</given-names></string-name><etal>et al</etal></person-group>
<article-title>Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial</article-title>. <source>BMC Cancer</source><year>2021</year>;<volume>21</volume>:<fpage>300</fpage><pub-id pub-id-type="pmid">33757440</pub-id>
</mixed-citation></ref><ref id="znae327-B35"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Stoop</surname>
<given-names>TF</given-names>
</string-name>, <string-name><surname>Ghorbani</surname><given-names>P</given-names></string-name>, <string-name><surname>Scholten</surname><given-names>L</given-names></string-name>, <string-name><surname>Bergquist</surname><given-names>E</given-names></string-name>, <string-name><surname>Ateeb</surname><given-names>Z</given-names></string-name>, <string-name><surname>van Dieren</surname><given-names>S</given-names></string-name><etal>et al</etal></person-group>
<article-title>Total pancreatectomy as an alternative to high-risk pancreatojejunostomy after pancreatoduodenectomy: a propensity score analysis on surgical outcome and quality of life</article-title>. <source>HPB (Oxford)</source><year>2022</year>;<volume>24</volume>:<fpage>1261</fpage>&#x02013;<lpage>1270</lpage><pub-id pub-id-type="pmid">35031280</pub-id>
</mixed-citation></ref></ref-list></back></article>